Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer, Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | September 20, 2016 |
| End Date: | March 2020 |
| Contact: | Matthew Fillare |
| Email: | Matthew.Fillare@uphs.upenn.edu |
A Preliminary Evaluation of Uptake in Bone Metastases, Biodistribution and Excretion of the Novel Radiotracer [68Ga]P15-041 by PET/CT
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and
determination of human dosimetry.
determination of human dosimetry.
Inclusion Criteria:
- histologically confirmed prostate cancer. known or suspected bone metastases referred
for a clinical [99mTc]MDP scan
Exclusion Criteria:
- Estimated creatinine clearance (GFR) < 30 mL/min (calculated), history of
hyperparathyroidism, • Inability to tolerate imaging procedures in the opinion of an
investigator or treating physician, • Any current medical condition, illness, or
disorder as assessed by medical record review and/or self-reported that is considered
by a physician investigator to be a condition that could compromise participant safety
or successful participation in the study
We found this trial at
1
site
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
